ACAD (ACADIA Pharmaceuticals Inc.) Stock Financials & Earnings | Market Cap Arena

ACAD (ACADIA Pharmaceuticals Inc.) Stock Financials & Earnings | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

Mkt Cap$4B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$1.1B

Net Income (TTM)$391M

EPS (TTM)$2.29

Free Cash Flow (TTM)$105M

Gross Margin91.7%

Op. Margin9.8%

Net Margin36.5%

FCF Margin9.8%

P/S Ratio (TTM)3.6x

P/E Ratio (TTM)10.0x

YoY Rev Growth+11.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$118M	$117M	-$54M
Q2 23	$165M	$158M	$3M
Q3 23	$212M	$197M	-$58M
Q4 23	$231M	$213M	$35M
Q1 24	$206M	$183M	$15M
Q2 24	$242M	$224M	$30M
Q3 24	$250M	$232M	$32M
Q4 24	$260M	$238M	$154M
Q1 25	$244M	$224M	$19M
Q2 25	$265M	$244M	$32M
Q3 25	$279M	$257M	$36M
Q4 25	$284M	$258M	$17M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	7.5x	—
Q2 23	7.1x	—
Q3 23	6.2x	—
Q4 23	5.4x	—
Q1 24	4.8x	—
Q2 24	4.4x	127.6x
Q3 24	4.2x	30.4x
Q4 24	4.1x	17.2x
Q1 25	3.9x	17.0x
Q2 25	3.8x	17.6x
Q3 25	3.7x	14.9x
Q4 25	3.6x	10.0x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$18M	-$18M
Q2 23	$8M	$8M
Q3 23	-$59M	-$59M
Q4 23	$85M	$85M
Q1 24	$29M	$29M
Q2 24	$25M	$25M
Q3 24	$63M	$63M
Q4 24	$40M	$40M
Q1 25	$20M	-$79M
Q2 25	$64M	$162M
Q3 25	$74M	$74M
Q4 25	-$49M	-$53M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$50K
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$70K
Q4 24	$453K
Q1 25	$99M
Q2 25	$99M
Q3 25	$388K
Q4 25	$4M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+2.6%	-24.7%
Q2 23	+22.8%	-3.6%
Q3 23	+62.0%	+66.8%
Q4 23	+69.3%	+7.4%
Q1 24	+73.8%	+10.8%
Q2 24	+46.4%	+30.4%
Q3 24	+18.3%	-18.8%
Q4 24	+12.4%	-45.9%
Q1 25	+18.7%	+18.0%
Q2 25	+9.3%	+9.8%
Q3 25	+11.3%	+11.0%
Q4 25	+9.4%	+151.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$15M	12.4%
Q2 23	$15M	9.2%
Q3 23	$19M	8.8%
Q4 23	$18M	7.8%
Q1 24	$15M	7.2%
Q2 24	$16M	6.5%
Q3 24	$26M	10.4%
Q4 24	$10M	4.0%
Q1 25	$11M	4.7%
Q2 25	$14M	5.4%
Q3 25	$13M	4.7%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$69M	$101M
Q2 23	$59M	$96M
Q3 23	$157M	$98M
Q4 23	$67M	$111M
Q1 24	$60M	$108M
Q2 24	$76M	$117M
Q3 24	$67M	$133M
Q4 24	$101M	$130M
Q1 25	$78M	$126M
Q2 25	$78M	$134M
Q3 25	$88M	$133M
Q4 25	$85M	$156M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$291M	$112M	$403M
Q2 23	$108M	$267M	$375M
Q3 23	$98M	$248M	$346M
Q4 23	$189M	$250M	$439M
Q1 24	$205M	$266M	$471M
Q2 24	$177M	$324M	$501M
Q3 24	$155M	$410M	$565M
Q4 24	$320M	$436M	$756M
Q1 25	$218M	$464M	$682M
Q2 25	$254M	$508M	$762M
Q3 25	$258M	$589M	$847M
Q4 25	$820M	$642M	$1.5B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	162M	+0.2%
Q2 23	165M	+1.7%
Q3 23	164M	-0.5%
Q4 23	167M	+1.4%
Q1 24	167M	+0.1%
Q2 24	166M	-0.3%
Q3 24	166M	+0.0%
Q4 24	166M	+0.1%
Q1 25	168M	+0.8%
Q2 25	169M	+0.6%
Q3 25	171M	+1.2%
Q4 25	171M	+0.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$1K	97
FY 15	$381	160
FY 16	$47K	370
FY 17	$294K	425
FY 18	$520K	430
FY 19	$674K	503
FY 20	$735K	601
FY 21	$942K	514
FY 22	$1M	513
FY 23	$1M	598
FY 24	$1M	654
FY 25	$2M	654